Pfizer (NYSE:PFE) to go ex-dividend.
On 4/25/2019 Pfizer ( NYSE:PFE ) announced that it will be issuing a quarterly dividend in the amount of $0.36 down from $0.36 making the yield 3.63%.


Pfizer (NYSE:PFE) Ex- dividend date

Pfizer (NYSE:PFE) is set to go ex-dividend on and will be payable on 6/7/2019


Dividend History for Pfizer (NYSE:PFE)
The next payable dividend for Pfizer is scheduled for 6/7/2019. There is an annual dividend of $$1.44 with a yield of 3.62% The company’s dividend has increased by 6.70% on a 3 Year Average

Recent Dividend History for Pfizer (NYSE:PFE)

• On 12/17/2012 Pfizer announced a quarterly dividend of $0.24.
• On 4/25/2013 Pfizer announced a quarterly dividend of $0.24.
• On 6/27/2013 Pfizer announced a quarterly dividend of $0.24.
• On 10/24/2013 Pfizer announced a quarterly dividend of $0.24.
• On 12/16/2013 Pfizer announced a quarterly dividend of $0.26.
• On 4/25/2014 Pfizer announced a quarterly dividend of $0.26.

About Company
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. The company also provides consumer healthcare products that comprise over-the-counter medicines, including dietary supplement products under the Centrum, Caltrate, and Emergen-C names; pain management products under the Advil and ThermaCare names; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H names; and respiratory and personal care products under the Robitussin, Advil Cold & Sinus, and ChapStick names. In addition, it offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit, Ixifi Infliximab BS names. Further, the company is also involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Merck KGaA; licensing agreement with BionTech AG; and collaboration agreements with Merck & Co., Inc. and Eli Lilly & Company, as well as with Merck KGaA and Nektar Therapeutics to develop a therapy for treating pancreatic cancer. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Recent Insider Trading for Pfizer (NYSE:PFE)

• On 4/1/2019 Alexander R Mackenzie, Insider, sold 15,000 with an average share price of $42.83 per share and the total transaction amounting to $642,450.00.
• On 3/15/2019 Rady A Johnson, Insider, sold 8,700 with an average share price of $41.13 per share and the total transaction amounting to $357,831.00.
• On 3/4/2019 Dawn Rogers, EVP, sold 15,002 with an average share price of $42.98 per share and the total transaction amounting to $644,785.96.
• On 3/4/2019 Mikael Dolsten, Insider, sold 149,553 with an average share price of $43.55 per share and the total transaction amounting to $6,513,033.15.
• On 3/1/2019 Mikael Dolsten, Insider, sold 100,471 with an average share price of $43.56 per share and the total transaction amounting to $4,376,516.76.
• On 2/1/2019 Douglas M Lankler, EVP, sold 5,000 with an average share price of $42.75 per share and the total transaction amounting to $213,750.00.

Recent Analyst Rating for Pfizer (NYSE:PFE)

• On 4/19/2019 JPMorgan Chase & Co., Reiterated Rating, to Neutral with a price target of $46.00
• On 4/1/2019 Bank of America, Boost Price Target, fromBuy to Buy with a price target of $45.00 to $48.00
• On 2/20/2019 Citigroup, Reiterated Rating, fromSell to Neutral with a price target of $41.00
• On 2/19/2019 Cantor Fitzgerald, Reiterated Rating, to bought with a price target of $53.00
• On 1/31/2019 Argus, Upgrade, fromHold to Buy with a price target of $55.00
• On 1/31/2019 Credit Suisse Group, Upgrade, fromNeutral to Outperform

Recent Trading for Pfizer (NYSE:PFE)
Shares of Pfizer closed the previous trading session at with 39.17 shares trading hands.